Skip to main content

Human FMR1NB Gene ORF cDNA clone expression plasmid, C terminal His tag

Catalog Number: HGC877-CH

Gene
Species
Human
NCBI RefSeq
RefSeq ORF Size
768bp
Gene Synonym
CT37, NYSAR35, FLJ25736, NY-SAR-35, FMR1NB, HAGH
Sequence Description
Identical with the Gene Bank Ref. ID sequence.
Description
Full length Clone DNA of Human fragile X mental retardation 1 neighbor Gene ORF cDNA clone expression plasmid, C terminal His tag
Plasmid
Promoter
Enhanced CMV mammalian cell promoter
Vector
pCMV3-C-His
Restriction Site
Protein Tag
His
Tag Sequence
CACCATCACCACCATCATCACCACCATCAC
Sequencing Primers
Forward:T7(TAATACGACTCACTATAGGG) Reverse:BGH(TAGAAGGCACAGTCGAGG)
Quality Control
The plasmid is confirmed by full-length sequencing.
His Tag Information
<p style="text-align: justify; "> A polyhistidine-tag is an amino acid motif in proteins that consists of at least five histidine (His) residues, often at the N- or C-terminus of the protein. </p> <p style="text-align: justify; "> Polyhistidine-tags are often used for affinity purification of polyhistidine-tagged recombinant proteins expressed in Escherichia coli and other prokarfyotic expression systems. </p>
Screening
Antibiotic in E. coli
Kanamycin
Antibiotic in Mammalian Cells
Hygromycin
Application
Stable or transient mammalian expression
Storage & Shipping
Shipping
Each tube contains lyophilized plasmid.
Storage
The lyophilized plasmid can be stored at ambient temperature for three months.
Background Information
A novel CT antigen, NY-SAR-35, mapping to chromosome Xq28 was identified among the cancer-related antigens, and encodes a putative extracellular protein. In addition to testis-restricted expression, NY-SAR-35 mRNA was expressed in sarcoma, melanoma, esophageal cancer, lung cancer and breast cancer. NY-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunotherapies.
References
  • Lee S Y, Obata Y, Yoshida M, et al. Immunomic analysis of human sarcoma[J]. Proceedings of the National Academy of Sciences, 2003, 100(5): 2651-2656.
  • TOP